Clinical Approach to Infertility
Comprehensive Practical Framework1. Symptom Overview
Understanding the clinical significance and classification of infertility
Infertility affects approximately 10-15% of couples of reproductive age worldwide, representing one of the most common reasons for gynecological consultation. In the United States alone, approximately 6.1 million women aged 15-44 have difficulty getting pregnant or carrying a pregnancy to term. The burden of infertility extends beyond the biological inability to conceive, significantly impacting psychological well-being, relationships, and quality of life. Despite advances in assisted reproductive technologies, the initial clinical approach to the infertile couple remains fundamental to identifying treatable causes and guiding management.
Definition
Infertility is defined as the failure to achieve a clinical pregnancy after 12 months or more of regular unprotected sexual intercourse. In women aged 35 years or older, evaluation is warranted after 6 months of trying to conceive due to the accelerated decline in fertility with advancing age. Fecundability refers to the probability of achieving a pregnancy in one menstrual cycle, which is approximately 20-25% in healthy couples under age 30.
Key Epidemiological Facts
- Approximately 85% of couples will conceive within 12 months of regular unprotected intercourse
- Female factors account for approximately 35-40% of cases
- Male factors account for approximately 30-40% of cases
- Combined male and female factors occur in 20-30% of cases
- Unexplained infertility accounts for 10-15% of cases after complete evaluation
Classification by Type
| Category | Definition | Common Causes | Clinical Significance |
|---|---|---|---|
| Primary Infertility | Never achieved a pregnancy | Ovulatory dysfunction, tubal disease, severe male factor, congenital anomalies | Higher likelihood of more severe underlying pathology; requires comprehensive workup |
| Secondary Infertility | Previously achieved at least one pregnancy (regardless of outcome) | Acquired tubal disease, endometriosis progression, age-related decline, new male factor | Prior fertility suggests at least partial reproductive potential; search for acquired causes |
Classification by Duration and When to Evaluate
| Age Group | Duration Before Evaluation | Rationale | Monthly Fecundability Rate |
|---|---|---|---|
| Women under 35 years | 12 months | Natural conception rates still reasonable; allows adequate time for conception | 20-25% |
| Women 35-40 years | 6 months | Accelerated decline in ovarian reserve; earlier intervention improves outcomes | 15-20% |
| Women over 40 years | Immediate evaluation | Significant decline in fertility; time is critical for treatment success | 5-10% |
| Known risk factors (any age) | Immediate evaluation | History of pelvic inflammatory disease, endometriosis, chemotherapy, or known male factor | Variable depending on pathology |
Classification by Etiology
Female Factors (35-40%)
Ovulatory dysfunction: Polycystic ovary syndrome, hypothalamic amenorrhea, hyperprolactinemia, premature ovarian insufficiency
Tubal and pelvic factors: Tubal occlusion, pelvic adhesions, hydrosalpinx, previous pelvic surgery
Uterine factors: Fibroids (especially submucosal), polyps, intrauterine adhesions, congenital anomalies
Cervical factors: Cervical stenosis, previous cervical surgery, hostile cervical mucus (rare)
Male Factors (30-40%)
Pre-testicular: Hypogonadotropic hypogonadism, hyperprolactinemia, exogenous testosterone use
Testicular: Varicocele, cryptorchidism, Klinefelter syndrome, chemotherapy/radiation damage
Post-testicular: Obstructive azoospermia, ejaculatory dysfunction, antisperm antibodies
Sperm function: Abnormal morphology, poor motility, DNA fragmentation
The Impact of Age on Fertility
| Age Range | Cumulative Pregnancy Rate (12 months) | Egg Quality | Ovarian Reserve |
|---|---|---|---|
| Under 30 years | 75-85% | Optimal | Abundant |
| 30-34 years | 65-75% | Good | Adequate |
| 35-37 years | 55-65% | Beginning to decline | Declining |
| 38-40 years | 40-50% | Significantly reduced | Reduced |
| Over 40 years | Less than 30% | Poor | Severely diminished |
The Core Principle: Successful conception requires four essential components working together:
- Ovulation — Regular release of a mature oocyte
- Adequate sperm — Sufficient quantity and quality of spermatozoa
- Patent reproductive tract — Open fallopian tubes allowing sperm-egg interaction
- Receptive uterine environment — Endometrium capable of supporting implantation
The initial evaluation should systematically assess each of these components.
Psychosocial Impact
Recognizing the Emotional Burden
Infertility is associated with significant psychological distress comparable to that experienced by patients with cancer, HIV, and chronic pain conditions. Studies show that:
- Approximately 40% of women undergoing fertility treatment experience depressive symptoms
- Anxiety disorders are common and may intensify with prolonged treatment
- Relationship strain occurs in approximately 25% of couples
- Social isolation and stigma remain significant concerns in many cultures
A compassionate, supportive approach throughout the evaluation and treatment process is essential.
2. Pathophysiology and Mechanisms
Understanding the underlying mechanisms of infertility
Successful reproduction requires a precisely orchestrated sequence of events involving the hypothalamic-pituitary-gonadal axis, the reproductive tract, and complex molecular signaling between gametes and the uterine environment. Understanding the pathophysiology of infertility begins with appreciating normal reproductive physiology and how disruption at any level can impair fertility.
The Hypothalamic-Pituitary-Ovarian Axis
| Level | Key Hormones/Structures | Function | Dysfunction Leads To |
|---|---|---|---|
| Hypothalamus | Gonadotropin-releasing hormone (GnRH) | Pulsatile secretion stimulates pituitary gonadotropin release | Hypothalamic amenorrhea, Kallmann syndrome, functional suppression |
| Anterior Pituitary | Follicle-stimulating hormone (FSH), Luteinizing hormone (LH) | FSH stimulates follicle growth; LH triggers ovulation and supports corpus luteum | Pituitary adenomas, Sheehan syndrome, hyperprolactinemia |
| Ovary | Estrogen, progesterone, inhibin, anti-Müllerian hormone | Folliculogenesis, oocyte maturation, hormone production | Premature ovarian insufficiency, polycystic ovary syndrome |
| Uterus | Endometrium | Proliferation and secretory transformation for implantation | Asherman syndrome, thin endometrium, luteal phase defect |
Normal Menstrual Cycle Physiology
Follicular Phase (Days 1-14)
GnRH pulses: Increase in frequency and amplitude
FSH rises: Recruits cohort of antral follicles
Dominant follicle: Selected by day 5-7, produces increasing estrogen
Estrogen effect: Endometrial proliferation, cervical mucus changes
Negative feedback: Rising estrogen suppresses FSH
Ovulation and Luteal Phase (Days 14-28)
LH surge: Triggered by sustained high estrogen levels
Ovulation: Occurs 34-36 hours after LH surge
Corpus luteum: Forms from remnant follicle, produces progesterone
Progesterone effect: Secretory transformation of endometrium
Luteolysis: If no pregnancy, corpus luteum regresses after 14 days
How Different Conditions Cause Infertility
Ovulatory Dysfunction Mechanisms
| Condition | Pathophysiological Mechanism | Treatment Implication |
|---|---|---|
| Polycystic ovary syndrome | Hyperandrogenism and insulin resistance lead to arrested follicular development; elevated LH:FSH ratio; anovulation despite numerous antral follicles | Ovulation induction with letrozole or clomiphene citrate; insulin sensitizers may improve response |
| Hypothalamic amenorrhea | Suppressed GnRH pulsatility due to energy deficit, stress, or excessive exercise; low FSH and LH lead to absent follicular development | Address underlying cause; pulsatile GnRH or exogenous gonadotropins if lifestyle modification insufficient |
| Hyperprolactinemia | Elevated prolactin inhibits GnRH pulsatility; causes hypogonadotropic hypogonadism and anovulation | Dopamine agonists (cabergoline) normalize prolactin and restore ovulation |
| Premature ovarian insufficiency | Depletion or dysfunction of primordial follicle pool before age 40; elevated FSH unable to stimulate follicle development | Limited options; donor oocytes often required for conception |
| Thyroid dysfunction | Hypothyroidism: Elevated thyrotropin-releasing hormone stimulates prolactin secretion; alters GnRH pulsatility. Hyperthyroidism: Increases sex hormone-binding globulin, affects steroid metabolism | Normalize thyroid function with appropriate treatment |
Tubal and Peritoneal Factor Mechanisms
| Condition | Pathophysiological Mechanism | Treatment Implication |
|---|---|---|
| Pelvic inflammatory disease | Ascending infection causes inflammation, fibrosis, and scarring of fallopian tubes; damages ciliated epithelium; creates tubal occlusion or hydrosalpinx | In vitro fertilization bypasses tubal function; salpingectomy for hydrosalpinx improves IVF success |
| Endometriosis | Ectopic endometrial tissue creates inflammatory environment; distorts pelvic anatomy; toxic effect on oocytes and sperm; impaired implantation | Surgical excision may improve natural conception; moderate-severe disease often requires in vitro fertilization |
| Previous pelvic surgery | Post-surgical adhesion formation; tubal damage; altered tubo-ovarian relationship prevents oocyte capture | Adhesiolysis may help; in vitro fertilization if significant tubal damage |
| Hydrosalpinx | Fluid-filled, damaged tube; retrograde flow of toxic fluid into uterine cavity impairs implantation; embryotoxic effect | Salpingectomy or proximal tubal occlusion before in vitro fertilization improves pregnancy rates |
Uterine Factor Mechanisms
| Condition | Pathophysiological Mechanism | Treatment Implication |
|---|---|---|
| Submucosal fibroids | Distort uterine cavity; alter endometrial blood flow; mechanical interference with implantation; may increase uterine contractility | Hysteroscopic myomectomy improves fertility outcomes |
| Endometrial polyps | Local inflammatory effect; mechanical barrier to implantation; associated with abnormal uterine bleeding | Polypectomy improves conception rates |
| Intrauterine adhesions (Asherman syndrome) | Scar tissue obliterates uterine cavity; reduces functional endometrium; impairs implantation | Hysteroscopic adhesiolysis with post-operative estrogen therapy |
| Müllerian anomalies | Congenital malformations (septate, bicornuate, unicornuate uterus); may affect implantation or increase pregnancy loss | Septum resection for uterine septum; other anomalies managed expectantly or surgically based on type |
Male Factor Pathophysiology
Normal Spermatogenesis
Key Points:
- Spermatogenesis takes approximately 72 days from spermatogonia to mature sperm
- Sperm maturation in the epididymis requires an additional 2-3 weeks
- Temperature regulation is critical — testicular temperature must be 2-4°C below core body temperature
- FSH acts on Sertoli cells to support spermatogenesis; LH stimulates Leydig cells to produce testosterone
- Testosterone is essential for spermatogenesis; exogenous testosterone paradoxically suppresses sperm production
Mechanisms of Male Infertility
| Category | Condition | Mechanism |
|---|---|---|
| Pre-testicular | Hypogonadotropic hypogonadism | Insufficient FSH and LH stimulation leads to impaired spermatogenesis; causes include pituitary tumors, Kallmann syndrome, exogenous steroids |
| Pre-testicular | Exogenous testosterone/anabolic steroids | Suppresses hypothalamic-pituitary axis; causes profound suppression of FSH and LH; may cause azoospermia |
| Testicular | Varicocele | Dilated pampiniform plexus veins increase testicular temperature; oxidative stress; reflux of toxic metabolites |
| Testicular | Cryptorchidism | Undescended testis exposed to higher abdominal temperature; impaired spermatogenesis; risk persists even after orchiopexy |
| Testicular | Klinefelter syndrome (47,XXY) | Extra X chromosome leads to testicular fibrosis and hyalinization; progressive deterioration of spermatogenesis |
| Post-testicular | Obstructive azoospermia | Blockage of vas deferens or epididymis; sperm production intact but cannot reach ejaculate; causes include vasectomy, congenital bilateral absence of vas deferens, infection |
| Post-testicular | Ejaculatory dysfunction | Retrograde ejaculation (diabetes, surgery); anejaculation (spinal cord injury); erectile dysfunction |
Often Overlooked Mechanism: Exogenous Testosterone
One of the most commonly missed causes of male infertility is exogenous testosterone use. Many patients do not volunteer this information, and some are unaware that testosterone supplementation suppresses their own sperm production. Testosterone and anabolic steroids cause profound suppression of the hypothalamic-pituitary-gonadal axis, often resulting in azoospermia. Recovery of spermatogenesis after cessation can take 6-12 months or longer, and in some cases may be permanent. Always ask specifically about testosterone injections, gels, patches, pellets, and anabolic steroids.
Unexplained Infertility: What We Do Not Know
The Mystery of Unexplained Infertility
In 10-15% of couples, standard evaluation reveals no identifiable cause. Potential undetected mechanisms include:
- Subtle oocyte quality defects: Not measurable by current testing
- Sperm function abnormalities: Normal semen parameters but impaired fertilization capacity
- Gamete transport issues: Impaired tubal function not detected by hysterosalpingography
- Fertilization defects: Problems with sperm-egg binding or fusion
- Implantation window abnormalities: Endometrial receptivity issues
- Genetic factors: Subtle chromosomal abnormalities or DNA fragmentation
Pathophysiology of Age-Related Fertility Decline
Oocyte Quantity
Peak: 6-7 million oocytes at 20 weeks gestation
Birth: 1-2 million oocytes
Puberty: 300,000-500,000 oocytes
Age 37: Approximately 25,000 oocytes (accelerated decline begins)
Menopause: Less than 1,000 oocytes
Oocyte Quality
Meiotic errors: Increase exponentially with age
Aneuploidy rate: From 10-15% at age 30 to over 50% at age 40
Mitochondrial dysfunction: Decreased energy production for cell division
DNA damage: Accumulated oxidative stress over time
Endometrial Factors
Blood flow: May decrease with age
Receptivity: Possibly diminished
Note: Egg quality is the primary factor — donor egg success rates remain high in older recipients
3. History Taking
A comprehensive approach to eliciting the infertility history
Red Flags — Require Prompt Evaluation or Referral
- Woman over 35 years — Accelerated fertility decline; expedite workup
- Amenorrhea or oligomenorrhea — Suggests anovulation requiring investigation
- History of pelvic inflammatory disease — High risk of tubal damage
- Known endometriosis — Progressive disease; may require surgical intervention
- Previous ectopic pregnancy — Indicates possible tubal pathology
- History of chemotherapy or radiation — Risk of gonadal damage in both partners
- Cryptorchidism history — Associated with impaired spermatogenesis
- Azoospermia on semen analysis — Requires urgent specialist referral
- Premature ovarian insufficiency suspected — Hot flashes, irregular cycles before age 40
- Recurrent pregnancy loss — Three or more losses; distinct evaluation pathway
Critical Principle: Infertility is a condition of the couple. Both partners must be evaluated simultaneously from the outset. Delaying male evaluation until female workup is complete is a common mistake that wastes valuable time.
Systematic History: The “FERTILE” Approach
The FERTILE Mnemonic
Use the mnemonic “FERTILE” to ensure comprehensive history taking:
- F — Frequency and timing of intercourse: How often? Timed to ovulation? Duration of trying?
- E — Endocrine and menstrual history: Cycle regularity, ovulation symptoms, hormonal disorders
- R — Reproductive history: Previous pregnancies, outcomes, abortions, ectopic pregnancies
- T — Tubal and uterine risk factors: Pelvic infections, surgery, endometriosis, fibroids
- I — Investigations and treatments already done: Previous workup, medications tried, assisted reproduction
- L — Lifestyle factors: Smoking, alcohol, weight, exercise, stress, occupation
- E — Evaluate the male partner: Semen analysis, medical history, medications, lifestyle
Female Partner History
Menstrual and Ovulatory History
| Question | What You Are Assessing | Clinical Significance |
|---|---|---|
| “How long is your menstrual cycle?” | Cycle regularity | Regular cycles (24-35 days) strongly suggest ovulation; irregular cycles suggest anovulation |
| “Are your periods predictable?” | Ovulatory consistency | Variation greater than 7-9 days suggests oligo-ovulation |
| “Do you notice midcycle mucus changes or pain?” | Ovulation awareness | Mittelschmerz and egg-white cervical mucus suggest ovulation |
| “Do you have premenstrual symptoms?” | Luteal phase function | Breast tenderness, bloating, mood changes suggest progesterone production |
| “How heavy are your periods? Any clots?” | Uterine pathology | Heavy bleeding may suggest fibroids, polyps, or adenomyosis |
| “Any bleeding between periods or after intercourse?” | Cervical or uterine pathology | May indicate polyps, cervical lesions, or infection |
Reproductive History
| Question | What You Are Assessing | Clinical Significance |
|---|---|---|
| “Have you ever been pregnant before?” | Primary versus secondary infertility | Prior pregnancy (even if not live birth) indicates some fertility potential |
| “How did each pregnancy end?” | Pregnancy outcomes | Miscarriages, ectopic pregnancies, and terminations each have different implications |
| “Did you require fertility treatment to conceive previously?” | Prior fertility issues | May indicate ongoing underlying condition |
| “Have you had any pregnancy complications?” | Obstetric history | Postpartum hemorrhage requiring curettage may cause Asherman syndrome |
| “Have you ever had an ectopic pregnancy?” | Tubal damage | Significantly increases risk of tubal factor infertility and future ectopic |
Gynecological and Surgical History
| Suspected Cause | Key Features | Ask This Question |
|---|---|---|
| Pelvic inflammatory disease | History of sexually transmitted infections, pelvic pain | “Have you ever been treated for chlamydia, gonorrhea, or a pelvic infection?” |
| Endometriosis | Dysmenorrhea, dyspareunia, chronic pelvic pain | “Do you have severe pain with your periods? Pain during intercourse?” |
| Uterine fibroids | Heavy menstrual bleeding, pelvic pressure | “Have you been told you have fibroids? Do you have very heavy periods?” |
| Polycystic ovary syndrome | Irregular cycles, hirsutism, acne, obesity | “Do you have irregular periods? Excess facial hair or acne? Difficulty with weight?” |
| Premature ovarian insufficiency | Hot flashes, night sweats, vaginal dryness before age 40 | “Have you noticed hot flashes or changes in your periods suggesting early menopause?” |
| Intrauterine adhesions | History of uterine instrumentation, light or absent periods | “Have you had a D&C or any procedure inside your uterus? Have your periods become much lighter?” |
| Tubal surgery or sterilization | Prior tubal ligation or reversal | “Have you ever had your tubes tied or any surgery on your fallopian tubes?” |
Male Partner History
| Suspected Cause | Key Features | Ask This Question |
|---|---|---|
| Varicocele | Scrotal heaviness, visible dilated veins | “Have you noticed any swelling or heaviness in your scrotum, especially when standing?” |
| Cryptorchidism | History of undescended testis, orchiopexy | “Were you ever told you had an undescended testicle? Did you have surgery as a child?” |
| Exogenous testosterone use | Testosterone therapy, anabolic steroids | “Are you taking any testosterone — injections, gels, patches, or pellets? Any supplements for bodybuilding?” |
| Ejaculatory dysfunction | Retrograde ejaculation, anejaculation | “Do you notice a normal amount of fluid when you ejaculate? Any difficulty with ejaculation?” |
| Erectile dysfunction | Difficulty achieving or maintaining erection | “Do you have any difficulty with erections during intercourse?” |
| Infection history | Epididymitis, orchitis, mumps | “Have you ever had an infection in your testicles? Did you have mumps as an adult?” |
| Gonadotoxin exposure | Chemotherapy, radiation, occupational exposures | “Have you ever had chemotherapy or radiation? Any exposure to chemicals or heat at work?” |
| Obstructive azoospermia | Prior vasectomy, absent vas deferens | “Have you had a vasectomy? Have you fathered children before?” |
Sexual and Coital History
Essential Questions About Intercourse
These questions must be asked sensitively but directly:
- Frequency: “How often do you have intercourse?” (Optimal is every 1-2 days during fertile window)
- Timing: “Do you know when you ovulate? How do you track it?”
- Duration: “How long have you been trying to conceive without using contraception?”
- Coital difficulties: “Are you able to have intercourse without difficulty?”
- Lubricant use: “Do you use any lubricants?” (Many lubricants are spermicidal)
- Dyspareunia: “Do you experience pain during intercourse?” (May indicate endometriosis)
Medication and Substance History
Medications That Affect Female Fertility
- Nonsteroidal anti-inflammatory drugs: May impair ovulation if used chronically
- Antipsychotics: Can cause hyperprolactinemia and anovulation
- Metoclopramide: Raises prolactin levels
- Chemotherapeutic agents: Gonadotoxic effects
- Immunosuppressants: May affect fertility
- Thyroid medications: Both hypo- and hyperthyroidism affect fertility
Medications That Affect Male Fertility
- Testosterone and anabolic steroids: Suppress spermatogenesis profoundly
- 5-alpha reductase inhibitors: Finasteride, dutasteride affect semen parameters
- Alpha-blockers: May cause retrograde ejaculation
- Sulfasalazine: Reversibly impairs sperm production
- Calcium channel blockers: May affect sperm function
- Opioids: Suppress hypothalamic-pituitary-gonadal axis
- Selective serotonin reuptake inhibitors: May cause ejaculatory delay
Lifestyle and Environmental Factors
| Factor | Effect on Female Fertility | Effect on Male Fertility |
|---|---|---|
| Smoking | Accelerates ovarian aging; reduces success of assisted reproduction; increases miscarriage risk | Reduces sperm count, motility, and morphology; increases DNA fragmentation |
| Alcohol | Heavy use associated with ovulatory dysfunction and reduced fecundability | Reduces testosterone; affects spermatogenesis with heavy use |
| Obesity (BMI greater than 30) | Anovulation; reduced response to fertility treatment; increased miscarriage | Altered hormone levels; increased scrotal temperature; erectile dysfunction |
| Underweight (BMI less than 18.5) | Hypothalamic amenorrhea; anovulation | Reduced sperm production if severe |
| Excessive exercise | Hypothalamic suppression; amenorrhea | May reduce testosterone with extreme endurance training |
| Heat exposure | Not significant | Hot tubs, saunas, tight underwear, laptop use may impair spermatogenesis |
| Cannabis use | May affect ovulation and implantation | Reduces sperm count and motility |
| Caffeine | High intake (greater than 500 mg/day) may modestly reduce fecundability | Unclear effect; moderate intake likely acceptable |
Family History
Female Partner
- Early menopause in mother or sisters: Risk of premature ovarian insufficiency
- Endometriosis in first-degree relatives: Increased risk
- Polycystic ovary syndrome: Familial tendency
- Fragile X premutation carriers: Associated with premature ovarian insufficiency
- Thyroid disorders: Familial autoimmune conditions
- Recurrent pregnancy loss: May suggest genetic factors
Male Partner
- Cystic fibrosis: Associated with congenital bilateral absence of vas deferens
- Klinefelter syndrome or other chromosomal abnormalities: Family history of infertility
- Y-chromosome microdeletions: Inherited cause of azoospermia or severe oligospermia
- Cryptorchidism: May have familial tendency
4. Physical Examination
A systematic approach to examining both partners presenting with infertility
Systematic Framework: Both partners should be examined. The female examination focuses on signs of endocrine disorders, pelvic pathology, and anatomical abnormalities. The male examination evaluates testicular size and consistency, presence of varicocele, and signs of hypogonadism.
Female Partner Examination
General Inspection
- Body habitus: Calculate BMI — obesity (greater than 30) and underweight (less than 18.5) both affect fertility
- Fat distribution: Central obesity suggests insulin resistance and polycystic ovary syndrome
- Hirsutism: Excess terminal hair in androgen-dependent areas (upper lip, chin, chest, lower abdomen) — score using Ferriman-Gallwey scale
- Acne: Especially if severe or persistent into adulthood — suggests hyperandrogenism
- Acanthosis nigricans: Velvety hyperpigmentation in skin folds (neck, axillae, groin) — indicates insulin resistance
- Hair pattern: Temporal balding or male-pattern hair loss suggests androgen excess
- Signs of Turner syndrome: Short stature, webbed neck, widely spaced nipples, shield chest
Vital Signs
| Vital Sign | What to Look For | Clinical Significance |
|---|---|---|
| Blood Pressure | Hypertension | May indicate polycystic ovary syndrome with metabolic syndrome; important for pregnancy planning |
| Heart Rate | Tachycardia or bradycardia | May suggest thyroid dysfunction |
| BMI | Calculate from height and weight | BMI less than 18.5 or greater than 30 significantly impacts fertility and treatment success |
Thyroid Examination
- Goiter: Enlarged thyroid may indicate hypo- or hyperthyroidism
- Nodules: Palpable thyroid nodules require further evaluation
- Signs of hypothyroidism: Dry skin, bradycardia, delayed relaxation of reflexes, periorbital edema
- Signs of hyperthyroidism: Tremor, tachycardia, lid lag, warm moist skin
Breast Examination
- Tanner staging: Assess breast development — underdeveloped breasts may indicate hypogonadism
- Galactorrhea: Express nipples gently — milk discharge suggests hyperprolactinemia
Abdominal Examination
- Palpable masses: Large fibroids or ovarian cysts may be palpable abdominally
- Surgical scars: Previous abdominal surgery increases risk of adhesions
- Striae: Purple striae may indicate Cushing syndrome
- Hepatomegaly: Liver disease can affect hormone metabolism
Pelvic Examination
| Component | What to Assess | Abnormal Findings and Significance |
|---|---|---|
| External Genitalia | Clitoromegaly, labial fusion, hair distribution | Clitoromegaly suggests significant androgen excess; labial fusion may indicate congenital adrenal hyperplasia |
| Vagina | Patency, septum, discharge | Vaginal septum may indicate Müllerian anomaly; discharge suggests infection |
| Cervix | Position, appearance, discharge, cervical mucus | Stenotic cervix (following cone biopsy), abnormal discharge; assess mucus quality if near ovulation |
| Uterus | Size, shape, position, mobility, tenderness | Enlarged uterus suggests fibroids; fixed uterus suggests adhesions or endometriosis |
| Adnexa | Ovarian size, masses, tenderness | Enlarged ovaries may indicate polycystic ovaries or cysts; tender nodularity suggests endometriosis |
| Cul-de-sac | Nodularity, tenderness | Nodularity and tenderness in posterior cul-de-sac highly suggestive of endometriosis |
| Uterosacral ligaments | Nodularity, tenderness | Palpable nodules suggest deep infiltrating endometriosis |
Male Partner Examination
General Inspection
- Body habitus: Obesity associated with reduced testosterone and erectile dysfunction
- Gynecomastia: Breast tissue development suggests estrogen excess or androgen deficiency
- Hair distribution: Reduced body hair, absent beard may indicate hypogonadism
- Eunuchoid proportions: Arm span greater than height, long legs relative to trunk — suggests prepubertal hypogonadism
- Signs of Klinefelter syndrome: Tall stature, gynecomastia, small testes, eunuchoid proportions
Genital Examination
| Component | What to Assess | Abnormal Findings and Significance |
|---|---|---|
| Penis | Meatal position, phimosis, plaques | Hypospadias may affect sperm deposition; Peyronie plaques cause penile curvature |
| Testicular size | Use orchidometer — normal is 15-25 mL or 4-5 cm length | Small testes (less than 15 mL) suggest impaired spermatogenesis; seen in Klinefelter syndrome, prior damage |
| Testicular consistency | Should be firm and rubbery | Soft testes suggest impaired spermatogenesis; hard areas may indicate tumor |
| Epididymis | Palpate along posterior testis | Fullness or induration suggests obstruction; tenderness suggests epididymitis |
| Vas deferens | Palpate within spermatic cord bilaterally | Absent vas deferens suggests congenital bilateral absence of vas deferens (associated with cystic fibrosis mutations) |
| Varicocele | Examine standing, with and without Valsalva maneuver | Grade I: Palpable only with Valsalva; Grade II: Palpable at rest; Grade III: Visible (“bag of worms”) |
| Inguinal region | Scars, hernias | Prior inguinal surgery may damage vas deferens |
Varicocele Examination Technique
Varicoceles are best detected with the patient standing in a warm room. Examine the spermatic cord above each testis. Have the patient perform the Valsalva maneuver while you palpate — a varicocele will become more prominent. Approximately 90% occur on the left side due to the drainage of the left testicular vein into the left renal vein at a 90-degree angle. A new right-sided or bilateral varicocele in an older man should raise concern for retroperitoneal pathology obstructing venous drainage.
Expected Findings by Etiology
Female Conditions
| Condition | General Examination | Pelvic Examination | Other Findings |
|---|---|---|---|
| Polycystic ovary syndrome | Obesity, hirsutism, acne, acanthosis nigricans | Often normal; may have bilaterally enlarged ovaries | Elevated BMI, hypertension |
| Hypothalamic amenorrhea | Low BMI, signs of energy deficiency | Atrophic vaginal mucosa, small uterus | Bradycardia, hypothermia, lanugo hair in severe cases |
| Hyperprolactinemia | May be normal | Galactorrhea on breast examination | Visual field defects if pituitary macroadenoma |
| Endometriosis | Usually normal | Uterosacral nodularity, fixed retroverted uterus, adnexal tenderness | May have no findings despite significant disease |
| Uterine fibroids | Usually normal | Enlarged, irregular uterus | May be palpable abdominally if large |
| Premature ovarian insufficiency | May be normal; Turner syndrome features if genetic | Vaginal atrophy, small uterus and ovaries | Signs of estrogen deficiency |
Male Conditions
| Condition | General Examination | Genital Examination | Other Findings |
|---|---|---|---|
| Varicocele | Normal | Dilated pampiniform plexus, usually left-sided | May have ipsilateral testicular atrophy |
| Klinefelter syndrome | Tall stature, gynecomastia, eunuchoid proportions | Small, firm testes (usually less than 4 mL) | Reduced facial and body hair |
| Hypogonadotropic hypogonadism | May have anosmia (Kallmann syndrome), eunuchoid proportions | Small testes, reduced secondary sexual characteristics | Prepubertal appearance if congenital |
| Congenital bilateral absence of vas deferens | Normal | Absent vas deferens bilaterally on palpation; testes normal size | May have mild cystic fibrosis features |
| Previous cryptorchidism | Normal | Smaller ipsilateral testis; surgical scars | History of orchiopexy |
Important Teaching Point
Normal examination is common! Many causes of infertility present with entirely normal physical examination findings in both partners. Tubal factor infertility from prior pelvic inflammatory disease, unexplained infertility, subtle ovulatory dysfunction, and many male factor causes may have no detectable physical findings. A normal examination does not exclude significant pathology — laboratory and imaging investigations remain essential. Never reassure a couple based solely on normal examination findings.
5. Differential Diagnosis
Systematic approach organized by category and probability
Step-by-Step Approach to Infertility Diagnosis:
- Step 1: Confirm the definition is met — 12 months (or 6 months if age 35 or older) of regular unprotected intercourse
- Step 2: Evaluate both partners simultaneously — never delay male evaluation
- Step 3: Assess the four essential components — ovulation, sperm, tubes, and uterus
- Step 4: Recognize that multiple factors often coexist — complete the full workup even after finding one abnormality
Female Factor Infertility (35-40% of Cases)
Ovulatory Dysfunction (25-30% of female factor)
| Probability | Condition | Key Features | Diagnostic Clues |
|---|---|---|---|
| COMMON | Polycystic ovary syndrome | Oligomenorrhea or amenorrhea, hyperandrogenism, polycystic ovaries on ultrasound | Irregular cycles since menarche; hirsutism; elevated LH:FSH ratio; elevated androgens |
| COMMON | Hypothalamic amenorrhea | Low BMI, excessive exercise, stress; secondary amenorrhea | Low FSH and LH; low estradiol; history of weight loss, eating disorder, or intense training |
| LESS COMMON | Hyperprolactinemia | Galactorrhea, amenorrhea or oligomenorrhea, headaches | Elevated serum prolactin; MRI may show pituitary adenoma |
| LESS COMMON | Thyroid dysfunction | Symptoms of hypo- or hyperthyroidism; menstrual irregularity | Abnormal thyroid-stimulating hormone; easily treatable cause |
| LESS COMMON | Premature ovarian insufficiency | Secondary amenorrhea before age 40; vasomotor symptoms | Elevated FSH (greater than 25 mIU/mL on two occasions); low anti-Müllerian hormone; low antral follicle count |
| UNCOMMON | Congenital adrenal hyperplasia (non-classic) | Hirsutism, oligomenorrhea, may mimic polycystic ovary syndrome | Elevated 17-hydroxyprogesterone; family history |
| UNCOMMON | Sheehan syndrome | Postpartum hemorrhage; failure of lactation; amenorrhea | Panhypopituitarism; history of severe postpartum bleeding |
Tubal and Peritoneal Factor (25-35% of female factor)
| Probability | Condition | Key Features | Diagnostic Clues |
|---|---|---|---|
| COMMON | Pelvic inflammatory disease sequelae | History of sexually transmitted infection or pelvic infection; may be asymptomatic | Tubal occlusion or hydrosalpinx on hysterosalpingography; history of chlamydia or gonorrhea |
| COMMON | Endometriosis | Dysmenorrhea, dyspareunia, chronic pelvic pain; may be asymptomatic | Laparoscopy is gold standard; may see endometriomas on ultrasound; elevated CA-125 (non-specific) |
| LESS COMMON | Previous pelvic or abdominal surgery | History of appendectomy, ovarian surgery, bowel surgery | Pelvic adhesions causing tubal distortion; may have normal hysterosalpingography if tubes patent |
| LESS COMMON | Previous ectopic pregnancy | History of ectopic requiring surgery or medical management | Ipsilateral tubal damage; hysterosalpingography shows occlusion or abnormality |
| UNCOMMON | Tubal ligation (seeking reversal or in vitro fertilization) | Prior sterilization procedure | Known history; hysterosalpingography confirms occlusion |
| UNCOMMON | Genital tuberculosis | History of pulmonary tuberculosis; endemic area; amenorrhea | Tubal calcification on imaging; endometrial biopsy positive for acid-fast bacilli |
Uterine Factor (5-10% of female factor)
| Probability | Condition | Key Features | Diagnostic Clues |
|---|---|---|---|
| COMMON | Submucosal fibroids | Heavy menstrual bleeding; uterine enlargement | Saline infusion sonography or hysteroscopy shows intracavitary distortion |
| COMMON | Endometrial polyps | Intermenstrual bleeding; may be asymptomatic | Seen on saline infusion sonography or hysteroscopy |
| LESS COMMON | Intrauterine adhesions (Asherman syndrome) | History of uterine instrumentation; hypomenorrhea or amenorrhea | Filling defects on hysterosalpingography; confirmed by hysteroscopy |
| LESS COMMON | Uterine septum | May have recurrent pregnancy loss; often asymptomatic | Best diagnosed by three-dimensional ultrasound or MRI; distinguished from bicornuate uterus |
| UNCOMMON | Other Müllerian anomalies | Unicornuate, bicornuate, didelphys uterus | MRI for definitive diagnosis; may have associated renal anomalies |
Male Factor Infertility (30-40% of Cases)
| Probability | Condition | Approximate Frequency | Key Distinguishing Features |
|---|---|---|---|
| COMMON | Idiopathic oligoasthenoteratozoospermia | 30-40% of male factor | Abnormal semen parameters with no identifiable cause; diagnosis of exclusion |
| COMMON | Varicocele | 25-40% of infertile men | Palpable dilated veins; typically left-sided; may have testicular atrophy |
| LESS COMMON | Exogenous testosterone or anabolic steroid use | Increasingly common | History of testosterone therapy; suppressed FSH and LH; may cause azoospermia |
| LESS COMMON | Obstructive azoospermia | 15-20% of azoospermic men | Normal testicular size; normal FSH; absent or low-volume ejaculate may suggest obstruction |
| LESS COMMON | Previous cryptorchidism | Variable | History of undescended testis; may have unilateral testicular atrophy |
| LESS COMMON | Hypogonadotropic hypogonadism | 1-2% of male factor | Low testosterone with low or normal FSH and LH; may have anosmia (Kallmann syndrome) |
| UNCOMMON | Klinefelter syndrome (47,XXY) | 10-15% of azoospermic men | Small firm testes; tall stature; gynecomastia; elevated FSH; azoospermia |
| UNCOMMON | Congenital bilateral absence of vas deferens | 1-2% of male factor | Azoospermia; absent vas on examination; low ejaculate volume; associated with cystic fibrosis mutations |
| UNCOMMON | Y-chromosome microdeletions | 5-10% of severe oligospermia or azoospermia | Severe oligospermia or non-obstructive azoospermia; genetic testing required |
| UNCOMMON | Ejaculatory dysfunction | Variable | Retrograde ejaculation (diabetes, surgery); anejaculation (spinal cord injury) |
Unexplained and Combined Factor Infertility
Unexplained Infertility (10-15%)
Definition: No identifiable cause after complete standard evaluation of both partners
Requirements for diagnosis:
- Confirmed ovulation
- Patent fallopian tubes (at least one)
- Normal uterine cavity
- Normal semen analysis
Possible occult causes: Subtle oocyte or sperm quality issues, fertilization defects, implantation abnormalities, peritoneal factors not detected by hysterosalpingography
Combined Factor Infertility (20-30%)
Definition: Abnormalities identified in both partners
Clinical significance:
- More common than single-factor infertility
- Complete evaluation of both partners is essential
- Finding one abnormality does not exclude others
- Treatment must address all identified factors
Example: Mild male factor (oligospermia) combined with ovulatory dysfunction or tubal disease
Anatomical Approach to Female Infertility
Hypothalamic-Pituitary
Hypothalamic amenorrhea
Hyperprolactinemia
Pituitary adenoma
Sheehan syndrome
Kallmann syndrome
Ovarian
Polycystic ovary syndrome
Premature ovarian insufficiency
Diminished ovarian reserve
Resistant ovary syndrome
Ovarian neoplasm
Tubal and Peritoneal
Tubal occlusion (post-infectious)
Hydrosalpinx
Endometriosis
Pelvic adhesions
Previous ectopic pregnancy
Uterine and Cervical
Submucosal fibroids
Endometrial polyps
Intrauterine adhesions
Müllerian anomalies
Cervical stenosis
Age-Related Fertility Decline
Age is Not a “Diagnosis” — But It Is the Most Important Factor
While not a specific etiology, advanced reproductive age (typically defined as 35 years or older) is the single most important factor affecting fertility outcomes. Key points:
- Fecundability declines from approximately 25% per cycle at age 25 to approximately 10% at age 35 and less than 5% at age 40
- Oocyte aneuploidy rates increase from approximately 10% at age 30 to greater than 50% at age 40
- Miscarriage rates increase from approximately 10% at age 25 to greater than 50% at age 45
- Success rates with fertility treatment also decline significantly with age
- Expedited evaluation and treatment are essential in older patients
Quick Reference: “If You See This, Think This”
| Clinical Clue | Think This First | Next Step |
|---|---|---|
| Irregular cycles since menarche, hirsutism, obesity | Polycystic ovary syndrome | Check androgens, LH:FSH ratio; ultrasound for polycystic ovaries |
| Secondary amenorrhea, low BMI, excessive exercise | Hypothalamic amenorrhea | Check FSH, LH, estradiol (all low); exclude other causes |
| Galactorrhea with amenorrhea | Hyperprolactinemia | Check serum prolactin; MRI if elevated |
| Hot flashes, irregular cycles, age less than 40 | Premature ovarian insufficiency | Check FSH (elevated), anti-Müllerian hormone (low), estradiol (low) |
| History of chlamydia or pelvic inflammatory disease | Tubal factor infertility | Hysterosalpingography or laparoscopy |
| Severe dysmenorrhea, dyspareunia, chronic pelvic pain | Endometriosis | Ultrasound for endometriomas; laparoscopy for definitive diagnosis |
| Heavy menstrual bleeding, enlarged uterus | Uterine fibroids | Pelvic ultrasound; saline infusion sonography for cavity evaluation |
| Hypomenorrhea after uterine instrumentation | Intrauterine adhesions (Asherman syndrome) | Hysterosalpingography or hysteroscopy |
| Male partner using testosterone therapy | Exogenous hormone-induced azoospermia | Stop testosterone; check FSH, LH, testosterone; repeat semen analysis in 3-6 months |
| Absent vas deferens on examination | Congenital bilateral absence of vas deferens | Cystic fibrosis mutation testing; genetic counseling; sperm retrieval for in vitro fertilization |
| Small firm testes, azoospermia, tall stature | Klinefelter syndrome | Karyotype analysis; testicular sperm extraction may be possible |
6. Diagnostic Investigations
A stepwise, evidence-based approach to infertility workup
Core Principle: The basic infertility workup should assess the four essential components of fertility:
- Ovulation — Is the woman ovulating regularly?
- Ovarian reserve — What is the remaining reproductive potential?
- Tubal patency — Are the fallopian tubes open?
- Semen quality — Are there adequate sperm?
Uterine cavity evaluation is also recommended, particularly before fertility treatment.
Basic Female Evaluation
Ovulation Assessment
| Test | Timing | What It Measures | Interpretation |
|---|---|---|---|
| Menstrual history | Initial visit | Cycle regularity and length | Regular cycles (24-35 days) strongly suggest ovulation; irregular cycles suggest anovulation |
| Midluteal progesterone | Day 21 of a 28-day cycle (or 7 days before expected menses) | Corpus luteum function | Greater than 3 ng/mL confirms ovulation; greater than 10 ng/mL suggests good luteal function |
| Urinary LH kit (ovulation predictor) | Begin testing 2-3 days before expected ovulation | LH surge preceding ovulation | Positive result indicates ovulation will occur in 24-36 hours; helps time intercourse |
| Basal body temperature charting | Daily throughout cycle | Biphasic temperature pattern | Rise of 0.2-0.5°C after ovulation due to progesterone; confirms ovulation retrospectively |
| Transvaginal ultrasound | Serial monitoring if needed | Follicular development; endometrial thickness | Dominant follicle 18-24 mm at ovulation; trilaminar endometrium; corpus luteum formation |
Ovarian Reserve Testing
| Test | Timing | Normal Values | Clinical Significance |
|---|---|---|---|
| Anti-Müllerian hormone (AMH) | Any day of cycle | 1.0-3.5 ng/mL (age-dependent) | Less than 1.0 ng/mL suggests diminished reserve; greater than 3.5 ng/mL may indicate polycystic ovary syndrome; predicts response to stimulation |
| Day 3 follicle-stimulating hormone (FSH) | Cycle day 2-4 | Less than 10 mIU/mL | Greater than 10 mIU/mL suggests diminishing reserve; greater than 15 mIU/mL indicates poor prognosis |
| Day 3 estradiol | Cycle day 2-4 | Less than 80 pg/mL | Elevated early estradiol (greater than 80 pg/mL) may falsely suppress FSH; indicates diminished reserve |
| Antral follicle count (AFC) | Cycle day 2-5 | 10-20 follicles (2-10 mm total) | Less than 5-7 suggests diminished reserve; greater than 20 may indicate polycystic ovary syndrome |
Understanding Ovarian Reserve Testing
Ovarian reserve tests predict the quantity of remaining oocytes and response to stimulation, but they do not predict oocyte quality or natural fertility. A woman with low ovarian reserve may still conceive naturally, while a woman with excellent reserve may have poor egg quality. These tests are most useful for:
- Predicting response to ovarian stimulation
- Counseling about urgency of treatment
- Individualizing stimulation protocols
- Discussing fertility preservation options
Tubal Patency Assessment
| Test | Method | Advantages | Limitations |
|---|---|---|---|
| Hysterosalpingography (HSG) | Radiographic imaging with radio-opaque contrast injected through cervix | Outpatient procedure; evaluates tubal patency and uterine cavity; may have therapeutic effect (oil-based contrast) | Does not assess peritubal adhesions or endometriosis; false positive rate for occlusion approximately 15% |
| Hysterosalpingo-contrast sonography (HyCoSy) | Ultrasound with saline or contrast through cervix | No radiation; can be done in office; simultaneous pelvic ultrasound | Operator dependent; may be less accurate than hysterosalpingography |
| Laparoscopy with chromopertubation | Surgical visualization with dye through tubes | Gold standard; allows treatment of pathology; directly visualizes endometriosis, adhesions | Invasive; requires anesthesia; higher cost; not first-line test |
Uterine Cavity Evaluation
| Test | Best For | Findings |
|---|---|---|
| Transvaginal ultrasound | Initial screening; fibroid mapping | Fibroids, endometrial thickness, ovarian cysts; limited for intracavitary lesions |
| Saline infusion sonography (SIS) | Intracavitary lesions; pretreatment evaluation | Polyps, submucosal fibroids, adhesions, septa — better than transvaginal ultrasound alone |
| Hysteroscopy | Definitive diagnosis and treatment of intracavitary lesions | Direct visualization; allows simultaneous polypectomy, myomectomy, adhesiolysis, septum resection |
| MRI pelvis | Müllerian anomaly characterization; adenomyosis; complex fibroids | Distinguishes septate from bicornuate uterus; maps deep infiltrating endometriosis |
Male Partner Evaluation
Semen Analysis — The Cornerstone
| Parameter | WHO 2021 Reference Values (5th percentile) | Clinical Significance |
|---|---|---|
| Volume | ≥1.4 mL | Low volume: retrograde ejaculation, hypogonadism, ejaculatory duct obstruction, incomplete collection |
| Sperm concentration | ≥16 million/mL | Oligozoospermia if below; severity graded as mild, moderate, severe |
| Total sperm count | ≥39 million per ejaculate | Better predictor of fertility than concentration alone |
| Progressive motility | ≥30% | Asthenozoospermia if below; affects ability to reach and fertilize oocyte |
| Total motility | ≥42% | Includes progressive and non-progressive motility |
| Morphology (strict criteria) | ≥4% normal forms | Teratozoospermia if below; affects fertilization rates |
| pH | ≥7.2 | Low pH may indicate ejaculatory duct obstruction or absence of seminal vesicle contribution |
| Vitality | ≥54% live sperm | Important when motility is low — distinguishes dead from immotile sperm |
Semen Analysis Practical Points
- Collection: 2-7 days of abstinence; collected by masturbation into sterile container
- Timing: Deliver to laboratory within 1 hour at body temperature
- Repeat if abnormal: At least one repeat analysis 2-4 weeks later — semen parameters vary significantly
- Recent illness: Febrile illness can affect spermatogenesis for 2-3 months
- Reference values are not fertility thresholds: Men with values below reference can still father children; values above do not guarantee fertility
Additional Male Testing (When Indicated)
| Test | Indication | What It Assesses |
|---|---|---|
| FSH, LH, testosterone | Azoospermia, severe oligospermia, clinical signs of hypogonadism | Distinguishes obstructive (normal hormones) from non-obstructive azoospermia (elevated FSH); identifies hypogonadotropic hypogonadism |
| Prolactin | Low testosterone, low libido, erectile dysfunction, gynecomastia | Hyperprolactinemia causes hypogonadotropic hypogonadism |
| Scrotal ultrasound | Palpable abnormality, small testes, suspected varicocele not clinically evident | Testicular volume, masses, varicocele, epididymal abnormalities |
| Transrectal ultrasound | Low ejaculate volume, azoospermia with dilated epididymis | Ejaculatory duct obstruction, seminal vesicle abnormalities |
| Karyotype | Azoospermia or severe oligospermia (less than 5 million/mL) | Klinefelter syndrome (47,XXY) and other chromosomal abnormalities |
| Y-chromosome microdeletion testing | Non-obstructive azoospermia or severe oligospermia (less than 5 million/mL) | AZFa, AZFb, AZFc deletions; prognostic for sperm retrieval; inheritable by male offspring |
| Cystic fibrosis mutation testing | Congenital bilateral absence of vas deferens | CFTR mutations; genetic counseling required before proceeding with sperm retrieval |
| Post-ejaculate urinalysis | Low ejaculate volume with normal orgasm | Sperm in urine confirms retrograde ejaculation |
| Sperm DNA fragmentation | Unexplained infertility, recurrent pregnancy loss, repeated IVF failure | Elevated DNA fragmentation may explain unexplained infertility; controversial clinical utility |
Additional Female Testing (When Indicated)
Endocrine Testing
- Thyroid-stimulating hormone (TSH): All women; optimal range 0.5-2.5 mIU/L for conception
- Prolactin: If irregular cycles, galactorrhea, or suspected pituitary disorder
- Androgens (testosterone, DHEAS): If hirsutism or suspected polycystic ovary syndrome
- 17-hydroxyprogesterone: If suspected non-classic congenital adrenal hyperplasia
- FSH, LH, estradiol: If amenorrhea or suspected ovarian insufficiency
- Fasting glucose and insulin: If suspected polycystic ovary syndrome or insulin resistance
Infectious and Immunological Testing
- Rubella immunity: Vaccinate before conception if non-immune
- Varicella immunity: Vaccinate before conception if non-immune
- HIV, hepatitis B and C: Recommended before fertility treatment
- Chlamydia screening: If not recently tested; treat before tubal evaluation
- Antiphospholipid antibodies: If recurrent pregnancy loss (not routine for infertility)
Stepwise Investigation Algorithm
First-Line Investigations for All Couples
- Confirm ovulation: Menstrual history; midluteal progesterone if cycles irregular
- Ovarian reserve testing: Anti-Müllerian hormone and/or day 3 FSH with estradiol; antral follicle count
- Semen analysis: At least one (repeat if abnormal)
- Tubal patency: Hysterosalpingography (or laparoscopy if high suspicion for endometriosis or pelvic disease)
- Uterine cavity: Transvaginal ultrasound at minimum; saline infusion sonography before treatment
- TSH: All women
- Rubella and varicella immunity: Preconception
When to Consider Diagnostic Laparoscopy
| Indication | Rationale | Potential Benefits |
|---|---|---|
| Suspected endometriosis (dysmenorrhea, dyspareunia, chronic pelvic pain) | Definitive diagnosis; stage disease | Excision may improve natural conception rates |
| Suspected pelvic adhesions (history of pelvic inflammatory disease, prior surgery) | Hysterosalpingography cannot assess peritubal adhesions | Adhesiolysis may restore tubal function |
| Abnormal hysterosalpingography suggesting tubal pathology | Confirm findings; assess tubal condition | Determine if tubal surgery versus in vitro fertilization appropriate |
| Unexplained infertility before proceeding to in vitro fertilization | May identify occult endometriosis or adhesions | Controversial; not routinely recommended but may be considered |
7. Pattern Recognition and Clinical Decision-Making
Practical algorithms and decision pathways for infertility management
Step 1: Is Expedited Evaluation Needed?
| Clinical Scenario | Urgency Level | Immediate Action |
|---|---|---|
| Woman over 40 years attempting conception | URGENT | Immediate referral to reproductive endocrinologist; begin workup without waiting 6-12 months |
| Woman 35-40 years, trying for 6 months | URGENT | Begin basic workup immediately; consider early referral if any abnormalities |
| Known risk factors (endometriosis, prior chemotherapy, cryptorchidism) | URGENT | Evaluate before attempting conception or after 3-6 months; do not wait full 12 months |
| Amenorrhea or severe oligomenorrhea | EXPEDITED | Evaluate ovulatory function immediately; anovulation confirmed — treatment indicated |
| Azoospermia on semen analysis | EXPEDITED | Confirm with repeat analysis; urgent urology referral for evaluation and possible sperm retrieval |
| Bilateral tubal occlusion on hysterosalpingography | EXPEDITED | Refer to reproductive endocrinologist; in vitro fertilization likely required |
| Woman under 35, regular cycles, trying less than 12 months | ROUTINE | Reassurance; optimize timing of intercourse; offer preconception counseling; evaluate at 12 months |
| Woman under 35, regular cycles, trying 12 months or more | ROUTINE | Begin standard infertility workup for both partners |
Step 2: Age-Based Management Pathway
Under 35 Years
Timeline: Evaluate after 12 months
Approach: Complete basic workup; time for less aggressive treatment if mild abnormalities
Treatment ladder: Lifestyle optimization → ovulation induction → intrauterine insemination → in vitro fertilization
35-40 Years
Timeline: Evaluate after 6 months
Approach: Expedited workup; move to treatment quickly; consider early referral to specialist
Treatment ladder: Abbreviated — may proceed to in vitro fertilization earlier if poor prognosis
Over 40 Years
Timeline: Evaluate immediately
Approach: Urgent specialist referral; discuss realistic expectations; consider donor oocytes
Treatment: In vitro fertilization often first-line; time is critical
Step 3: Algorithm Based on Ovulatory Status
Algorithm A: Anovulatory Infertility
| Clinical Scenario | Most Likely Diagnosis | First-Line Action |
|---|---|---|
| Irregular cycles, hirsutism, obesity, acanthosis nigricans | Polycystic ovary syndrome | Weight loss if obese; ovulation induction with letrozole (first-line) or clomiphene citrate |
| Amenorrhea, low BMI, excessive exercise, stress | Hypothalamic amenorrhea | Address underlying cause (weight gain, reduce exercise, stress management); if unsuccessful, gonadotropins or pulsatile GnRH |
| Galactorrhea, amenorrhea, headaches, visual changes | Hyperprolactinemia | MRI pituitary; dopamine agonist (cabergoline) normalizes prolactin and restores ovulation |
| Irregular cycles, fatigue, weight changes, cold intolerance | Thyroid dysfunction | Normalize thyroid-stimulating hormone with levothyroxine or antithyroid medication |
| Amenorrhea, hot flashes, elevated FSH, age less than 40 | Premature ovarian insufficiency | Hormone replacement therapy; counsel regarding limited treatment options; donor oocytes if pregnancy desired |
Algorithm B: Ovulatory Infertility with Tubal or Uterine Factor
| Clinical Scenario | Diagnosis | Management Approach |
|---|---|---|
| Bilateral tubal occlusion on hysterosalpingography | Tubal factor infertility | In vitro fertilization (bypasses tubes); tubal surgery rarely indicated except in selected cases |
| Unilateral tubal occlusion, other tube patent | Unilateral tubal disease | May attempt natural conception or intrauterine insemination; proceed to in vitro fertilization if unsuccessful |
| Hydrosalpinx visible on ultrasound or hysterosalpingography | Hydrosalpinx | Salpingectomy or proximal tubal occlusion before in vitro fertilization (improves success rates) |
| Submucosal fibroid distorting cavity | Submucosal leiomyoma | Hysteroscopic myomectomy before attempting conception or fertility treatment |
| Endometrial polyp on saline infusion sonography | Endometrial polyp | Hysteroscopic polypectomy improves conception rates |
| Intrauterine adhesions, hypomenorrhea | Asherman syndrome | Hysteroscopic adhesiolysis with estrogen therapy post-procedure |
| Uterine septum on imaging | Septate uterus | Hysteroscopic septum resection (especially if recurrent pregnancy loss) |
Algorithm C: Male Factor Infertility
| Semen Analysis Finding | Further Evaluation | Treatment Options |
|---|---|---|
| Mild oligospermia (10-15 million/mL) | Repeat semen analysis; check for varicocele; lifestyle optimization | Intrauterine insemination; in vitro fertilization if intrauterine insemination fails |
| Moderate oligospermia (5-10 million/mL) | Hormone testing; scrotal ultrasound; consider varicocele repair if present | In vitro fertilization with intracytoplasmic sperm injection often recommended |
| Severe oligospermia (less than 5 million/mL) | Full endocrine workup; karyotype; Y-chromosome microdeletion testing | In vitro fertilization with intracytoplasmic sperm injection; genetic counseling |
| Azoospermia with normal FSH and normal testicular size | Suspect obstructive azoospermia; transrectal ultrasound; consider vasography | Surgical sperm retrieval (microsurgical epididymal sperm aspiration, testicular sperm extraction) with in vitro fertilization and intracytoplasmic sperm injection |
| Azoospermia with elevated FSH and small testes | Non-obstructive azoospermia; karyotype; Y-chromosome microdeletion testing | Micro-testicular sperm extraction may retrieve sperm in some cases; donor sperm if unsuccessful |
| History of testosterone or anabolic steroid use | Stop exogenous hormones; repeat semen analysis in 3-6 months | Recovery may take 6-12 months or longer; may need clomiphene or human chorionic gonadotropin to stimulate recovery |
| Absent vas deferens bilaterally | Cystic fibrosis mutation testing for both partners; renal ultrasound | Surgical sperm retrieval with in vitro fertilization and intracytoplasmic sperm injection; preimplantation genetic testing if both partners carry cystic fibrosis mutations |
Step 4: Approach to Unexplained Infertility
Definition: Normal ovulation, patent tubes, normal uterine cavity, normal semen analysis
Management Options (in order of increasing intensity):
- Expectant management: Reasonable for young couples (under 35) with short duration — cumulative pregnancy rate approximately 2-4% per month
- Ovarian stimulation with timed intercourse: Letrozole or clomiphene citrate; modest improvement in pregnancy rates
- Intrauterine insemination with ovarian stimulation: Success rate approximately 8-15% per cycle; reasonable for 3-4 cycles
- In vitro fertilization: Highest success rates; recommended if above treatments fail or if age is a concern
“What Do I Do If…” Decision Reference
| Clinical Situation | Immediate Action | Next Step |
|---|---|---|
| Woman requests fertility testing but is not ready to conceive | Offer ovarian reserve testing (anti-Müllerian hormone, antral follicle count); discuss fertility preservation options | Counsel about age-related decline; refer for oocyte cryopreservation if desired |
| Woman over 35 with diminished ovarian reserve | Urgent specialist referral; discuss time-sensitive nature | Aggressive treatment (in vitro fertilization) may be first-line; consider donor oocytes if reserve very low |
| Male partner refuses evaluation | Emphasize importance; explain that male factor accounts for 30-40% of infertility | Cannot proceed appropriately without male evaluation; at minimum need semen analysis |
| Both partners have identified abnormalities | Address all factors; do not stop workup after finding one cause | Treatment plan must consider combined factors; may need in vitro fertilization |
| Patient has had 3 failed intrauterine insemination cycles | Discuss diminishing returns of further intrauterine insemination | Recommend in vitro fertilization; success rates significantly higher |
| Anti-Müllerian hormone is undetectable | Confirm ovarian insufficiency with FSH; discuss limited options | Counsel about poor prognosis; donor oocytes offer best chance of pregnancy |
| Patient asks about “natural” fertility treatments | Listen to concerns; review evidence (limited for most supplements) | Optimize modifiable factors (weight, smoking, alcohol); do not delay evidence-based treatment |
| Patient cannot afford in vitro fertilization | Explore coverage options; discuss less expensive alternatives | Maximise intrauterine insemination cycles; discuss financing programs, shared-risk programs, or lower-cost international options |
When to Refer to a Reproductive Endocrinologist
Indications for Specialist Referral
- Woman over 35 years with infertility (earlier referral recommended)
- Woman over 40 years attempting conception (immediate referral)
- Diminished ovarian reserve (low anti-Müllerian hormone, elevated FSH)
- Bilateral tubal occlusion requiring in vitro fertilization
- Moderate to severe male factor requiring intracytoplasmic sperm injection
- Azoospermia requiring surgical sperm retrieval
- Failed ovulation induction (3-6 cycles)
- Failed intrauterine insemination (3-4 cycles)
- Endometriosis requiring advanced treatment
- Recurrent pregnancy loss (3 or more losses)
- Need for preimplantation genetic testing
- Fertility preservation before gonadotoxic treatment
Troubleshooting Treatment Failure
Questions to Ask When Treatment Fails
- Was the diagnosis complete? Re-evaluate both partners; consider laparoscopy if not done
- Is there an occult male factor? Consider sperm DNA fragmentation testing
- Is there undiagnosed endometriosis? Laparoscopy may reveal peritoneal disease not detected by imaging
- Is there an implantation issue? Review uterine cavity evaluation; consider hysteroscopy
- Are there lifestyle factors? Address smoking, obesity, excessive alcohol
- Is it time to escalate treatment? Move from intrauterine insemination to in vitro fertilization
- Should donor gametes be considered? If severe male factor or diminished ovarian reserve
- Is a gestational carrier needed? If uterine factor cannot be corrected
8. Clinical Pearls and Pitfalls
Practical wisdom — learn from successes and avoid common mistakes
Must-Know Clinical Pearls
Infertility is a couple’s diagnosis: Always evaluate both partners from the beginning. Delaying male evaluation until female workup is complete wastes precious time — especially in older couples.
Age is the most important prognostic factor: A 25-year-old with bilateral tubal occlusion has a better prognosis with in vitro fertilization than a 42-year-old with unexplained infertility. Egg quality declines exponentially after age 35.
Regular cycles strongly predict ovulation: Women with regular menstrual cycles (24-35 days, variation less than 7 days) are ovulating more than 95% of the time. Extensive ovulation testing is often unnecessary in these patients.
Ask every man about testosterone: Exogenous testosterone use is an increasingly common and frequently missed cause of male infertility. It can cause complete azoospermia and patients often do not volunteer this information.
One abnormality does not exclude others: Combined factor infertility is common (20-30% of cases). Finding polycystic ovary syndrome does not mean you can skip the hysterosalpingography or semen analysis.
Letrozole is first-line for ovulation induction in polycystic ovary syndrome: Multiple studies show letrozole results in higher ovulation and live birth rates than clomiphene citrate, with lower risk of multiple pregnancy.
Hydrosalpinx reduces in vitro fertilization success: Fluid from a hydrosalpinx is embryotoxic. Salpingectomy or proximal tubal occlusion before in vitro fertilization significantly improves pregnancy rates.
Anti-Müllerian hormone predicts quantity, not quality: A low anti-Müllerian hormone tells you about remaining egg numbers and response to stimulation, but a young woman with low anti-Müllerian hormone may still have good quality eggs and conceive naturally.
Critical Pitfalls to Avoid
Delaying evaluation in older women: Every month matters after age 35. Do not wait 12 months to begin workup — initiate evaluation after 6 months (or immediately if over 40).
Forgetting to evaluate the male partner: Up to 40% of infertility involves male factors. A semen analysis should be obtained early in the workup — not after exhaustive female testing.
Relying on a single semen analysis: Semen parameters vary significantly (up to 20-30% between samples). An abnormal result should always be confirmed with a repeat analysis 2-4 weeks later.
Missing exogenous testosterone use: Always ask specifically about testosterone therapy, including injections, gels, patches, pellets, and “supplements.” Many men are unaware this causes infertility.
Overlooking lifestyle factors: Smoking, obesity, excessive alcohol, and heat exposure (in men) are modifiable factors that significantly impact fertility. Address these while pursuing medical evaluation.
Stopping workup after finding one diagnosis: Combined factor infertility is common. A woman with polycystic ovary syndrome may also have tubal disease; a man with varicocele may also have genetic abnormalities.
Excessive intrauterine insemination cycles: Success rates decline after 3-4 cycles. Persisting with intrauterine insemination beyond this point delays more effective treatment (in vitro fertilization).
Ignoring the emotional burden: Infertility causes significant psychological distress. Acknowledge feelings, screen for depression and anxiety, and refer for counseling when appropriate.
Key Takeaways
- Infertility affects 10-15% of couples; evaluate after 12 months of trying (6 months if age 35 or older, immediately if over 40)
- Always evaluate both partners simultaneously — male factor accounts for 30-40% of cases
- The basic workup assesses four components: ovulation, ovarian reserve, tubal patency, and semen quality
- Regular menstrual cycles (24-35 days) strongly suggest ovulation is occurring
- Polycystic ovary syndrome is the most common cause of anovulatory infertility; letrozole is first-line treatment
- Tubal factor often results from prior pelvic inflammatory disease; in vitro fertilization bypasses damaged tubes
- Exogenous testosterone is an increasingly common cause of male infertility — always ask about it
- Anti-Müllerian hormone and antral follicle count predict ovarian reserve (quantity) but not egg quality
- Age is the most important factor — fertility declines significantly after 35 and dramatically after 40
- Unexplained infertility (10-15% of cases) is managed with ovarian stimulation, intrauterine insemination, or in vitro fertilization
- Move to in vitro fertilization after 3-4 failed intrauterine insemination cycles or earlier if poor prognostic factors
- Address the emotional burden — infertility causes stress comparable to chronic serious illness
Quick Reference Algorithm
Systematic Approach to Infertility:
- Confirm eligibility: Verify duration of trying (12 months, or 6 months if age ≥35) and regular unprotected intercourse
- Assess urgency: Expedite if woman is over 35, has known risk factors, or obvious abnormality (amenorrhea, azoospermia)
- Evaluate ovulation: Menstrual history; midluteal progesterone if cycles irregular
- Test ovarian reserve: Anti-Müllerian hormone and/or day 3 FSH; antral follicle count
- Obtain semen analysis: At least one; repeat if abnormal
- Assess tubal patency: Hysterosalpingography (or laparoscopy if high suspicion for endometriosis)
- Evaluate uterine cavity: Transvaginal ultrasound; saline infusion sonography before treatment
- Check thyroid function: Thyroid-stimulating hormone in all women
- Identify diagnosis: Ovulatory dysfunction, tubal factor, uterine factor, male factor, unexplained, or combined
- Formulate treatment plan: Address all identified factors; consider age and prognosis when selecting treatment intensity
- Refer appropriately: To reproductive endocrinology for advanced treatment, poor prognosis, or age over 35
- Support the couple: Acknowledge emotional impact; offer counseling resources